CJC-1295 is also known as DAC:GRF, which is short for drug affinity complex: growth hormone-releasing factor. It is a synthetic analogue of GHRH and a growth hormone secretagogue. CJC-1295 is known for increasing the plasma growth hormone known as GH as well as IGF-1.visit this link for more details.
Studies conducted by the Karolinska Institutet in Stockholm, Sweden has shown some great results in the application of CJC-1295. These studies have shown that CJC-1295 has the ability to increase growth hormone as well as IGF-1 secretions. Therefore, CJC-1295 has also shown to increase the benefits that goes along with this as well. These studies have also shown that application of CJC-1295 can maintain a steady increase of these substances.
Other studies, like the one conducted by Portland State University, has shown that CJC-1295 can also double the half-life and bioavailability of growth hormone-releasing hormone and stimulate IGF-1. It has also been shown to increase the half-life of acting agents by bioconjugation.
CJC-12-95 has also been involved in the investigation of the treatment of lipodystrophy as well as growth hormone deficiency. However, the further experimentation in this area was discontinued due to the death of one of the trial subjects. These studies were conducted by the University of Olso.
The question of how safe CJC-1295 has yet to be determined, despite all of the research that has already been conducted. Due to results of previous trials, scientists are treading lightly with this substance and research may possibly be slow-going at this point. However, this research is vital in determining how this substance can be utilized in the future.
Andersen Hartvig, Rune; Bjerre Holm, Niels; Weihe Dalsgaard, Petur; Ask Reitzel, Lotte; Breum Müller, Irene; Linnet, Kristian (2014). “Identification of peptide and protein doping related drug compounds confiscated in Denmark between 2007-2013”. Scandinavian Journal of Forensic Science 20 (2). doi:10.2478/sjfs-2014-0003.ISSN 2353-0707.
“Current Research Findings Regarding CJC-1295”. Neo Scientific.
Retrieved 3 August 2015. The reason why CJC1295 possesses the ability to lengthen the half-life within the active agent has to do with the scientific process known as bioconjugation. This technology, which is relatively new in nature, is defined by its ability to take a reactive group and bond it to a peptide (Aslam and Dent). This attachment causes a reaction with a nucleophilic unit; a typically partially molecule that is found within the bloodstream of an animal test subject.
This reaction in turn causes a more stable bond to occur. This specific peptide has an especially high attraction to albumin, a globular protein that is soluble in water. This affinity prohibits natural degradation, which in turn increases the peptide’s half-life (Hermanson). Additionally, clinical research performed on animal test subjects has thus far shown that there have been no signs of DPP-IV degradation present when CJC-1295 was introduced (Gonzalez, US Peptide Articles).
Jetté, Lucie; Léger, Roger; Thibaudeau, Karen; Benquet, Corinne; Robitaille, Martin; Pellerin, Isabelle; Paradis, Véronique; van Wyk, Pieter; Pham, Khan; Bridon, Dominique P. (2005). “Human Growth Hormone-Releasing Factor (hGRF)1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog”(PDF). Endocrinology 146 (7): 3052–3058.doi:10.1210/en.2004-1286. ISSN 0013-7227.PMID 15817669.
Peptide Sciences. “CJC-1295 DAC 5mg.” Highly Purified Peptides. n.d. Web. 2016 July 25.